<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2012-3-52-56</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL &amp; EXPERIMENTAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Комплексная модель оценки риска развития и прогрессирования возрастной макулярной дегенерации</article-title><trans-title-group xml:lang="en"><trans-title>The complex model of risk and progression of AMD estimation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акопян</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Akopyan</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор кафедры офтальмологии факультетафундаментальной медицины МГУ им. М.В. Ломоносова,</p></bio><email xlink:type="simple">akopyan_vs@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семенова</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Semenova</surname><given-names>N. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>E. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тонивицкий</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Tonivitskiy</surname><given-names>A. G.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нечаев</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Nechayev</surname><given-names>I. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Факультет фундаментальной медицины Московского государственного университета&#13;
им. М.В. Ломоносова, Москва, Россия</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ФГБУ «Научно-исследовательский институт общей патологии и патофизиологии» РАМН, Москва, Россия</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>15</day><month>07</month><year>2014</year></pub-date><volume>9</volume><issue>3</issue><fpage>52</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Акопян В.С., Семенова Н.С., Новикова Е.А., Тонивицкий А.Г., Нечаев И.Н., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Акопян В.С., Семенова Н.С., Новикова Е.А., Тонивицкий А.Г., Нечаев И.Н.</copyright-holder><copyright-holder xml:lang="en">Akopyan V.S., Semenova N.S., Novikova E.A., Tonivitskiy A.G., Nechayev I.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/155">https://www.ophthalmojournal.com/opht/article/view/155</self-uri><abstract><p>Цель. Разработка метода и статистической модели для оценки индивидуального риска возрастной макулярной дегенера- ции (ВМД) и риска прогрессирования ВМД до поздних стадий с учетом клинических и генетических факторов риска.Методы. Для составления статистических моделей оценки риска применялась бинарная логистическая регрессия с функцией последовательного включения и исключения признаков. Для оценки популяционных различий в распространен- ности аллельных вариантов генов и разработки адаптированной модели для популяции московского региона проведено генотипирование и оценка влияния других факторов риска в двух группах испытуемых: больные ВМД различной стадии (n = 74) и контрольная группа (n = 116). Генетические факторы риска, включенные в исследование: полиморфизмы генов си- стемы комплемента (С3 и CFH), полиморфизмы генов локуса 10q26 (ARMS2 и HtRA1), полиморфизм митохондриального гена Mt-ND2. Клинические факторы риска, включенные в исследование: возраст, пол, высокий индекс массы тела, стаж курения.Результаты. Проведен комплексный анализ генетических и клинических факторов риска ВМД в исследуемой группе. Составлена статистическая модель оценки индивидуального риска ВМД, чувствительность модели — 66,7%, специфич- ность — 78,5%, AUC = 0,76. Определены факторы риска поздней ВМД, составлена статистическая модель, описывающая вероятность поздней ВМД, чувствительность — 66,7%, специфичность — 78,3%, AUC = 0,73. Разработанная система по- зволяет определить наиболее вероятный вариант течения поздней ВМД — по экссудативному или неэкссудативному пути.Заключение. Разработанная тест-система и математический алгоритм определения риска развития и риска прогресси- рования ВМД имеют хорошую диагностическую информативность и перспективны для применения в клинической практике.</p></abstract><trans-abstract xml:lang="en"><p>Purpose: to develop a method and a statistical model to estimate individual risk of AMD and the risk for progression to advanced AMD using clinical and genetic risk factors.Methods: A statistical risk assessment model was developed using stepwise binary logistic regression analysis. to estimate the population differences in the prevalence of allelic variants of genes and for the development of models adapted to the population of Moscow region genotyping and assessment of the influence of other risk factors was performed in two groups: patients with differ- ent stages of AMD (n = 74), and control group (n = 116). Genetic risk factors included in the study: polymorphisms in the complement system genes (C3 and CFH), genes at 10q26 locus (ARMS2 and HtRA1), polymorphism in the mitochondrial gene Mt-ND2. Clinical risk factors included in the study: age, gender, high body mass index, smoking history.Results: A comprehensive analysis of genetic and clinical risk factors for AMD in the study group was performed. Compiled statis- tical model assessment of individual risk of AMD, the sensitivity of the model — 66.7%, specificity — 78.5%, AUC = 0.76. Risk factors of late AMD, compiled a statistical model describing the probability of late AMD, the sensitivity of the model — 66.7%, specificity — 78.3%, AUC = 0.73. the developed system allows determining the most likely version of the current late AMD: dry or wet.Conclusion: the developed test system and the mathematical algorhythm for determining the risk of AMD, risk of progression to advanced AMD have fair diagnostic informative and promising for use in clinical practice.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>возрастная макулярная дегенерация</kwd><kwd>факторы риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>AMD</kwd><kwd>risk factors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Smith A. F. The growing importance of pharmacoeconomics: the case of age-relat- ed macular degeneration // Br J Ophthalmol. — 2010. — Vol. 94. — P. 1116-1117.</mixed-citation><mixed-citation xml:lang="en">Smith A. F. The growing importance of pharmacoeconomics: the case of age-relat- ed macular degeneration // Br J Ophthalmol. — 2010. — Vol. 94. — P. 1116-1117.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Day S. A. et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007 // Am J Ophthalmol. — 2011. — Vol. 152. — P. 1014-1020.</mixed-citation><mixed-citation xml:lang="en">Day S. A. et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007 // Am J Ophthalmol. — 2011. — Vol. 152. — P. 1014-1020.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chew E. Y., Lindblad A. S., Clemons T. A. Summary results and recommendations from the age-related eye disease study // Arch Ophthalmol. — 2009. — Vol.127. — P. 1678-1679.</mixed-citation><mixed-citation xml:lang="en">Chew E. Y., Lindblad A. S., Clemons T. A. Summary results and recommendations from the age-related eye disease study // Arch Ophthalmol. — 2009. — Vol.127. — P. 1678-1679.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rauch R. R. et al. Time to first treatment: The Significance of Early Treatment of Ex- udative Age-related Macular Degeneration // Retina. — 2011. — Vol. 29. — P. 41-46.</mixed-citation><mixed-citation xml:lang="en">Rauch R. R. et al. Time to first treatment: The Significance of Early Treatment of Ex- udative Age-related Macular Degeneration // Retina. — 2011. — Vol. 29. — P. 41-46.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Scholl H. P. et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD // PLoSOne. — 2009. — Vol. 4. — P. 741-748.</mixed-citation><mixed-citation xml:lang="en">Scholl H. P. et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD // PLoSOne. — 2009. — Vol. 4. — P. 741-748.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Teper S. J., Nowińska A. E., Wylęgała E. S. A69S and R38X ARMS2 and Y402H CFH gene polymorphisms as risk factors for neovascular age-related macular degenera- tion in Poland — a brief report // Med SciMonit. — 2012. — Vol. 18. — P.21-23.</mixed-citation><mixed-citation xml:lang="en">Teper S. J., Nowińska A. E., Wylęgała E. S. A69S and R38X ARMS2 and Y402H CFH gene polymorphisms as risk factors for neovascular age-related macular degenera- tion in Poland — a brief report // Med SciMonit. — 2012. — Vol. 18. — P.21-23.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tong Y. J. et al. LOC387715 / HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis // Mol Vis. — 2010.— Vol. 16.— P. 1958-1981.</mixed-citation><mixed-citation xml:lang="en">Tong Y. J. et al. LOC387715 / HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis // Mol Vis. — 2010.— Vol. 16.— P. 1958-1981.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Klein M. L. et al. The Epidemiology of Age-Related Macular Degeneration // Am J Ophthalmol. — 2004. — Vol. 137. — P. 486-495.</mixed-citation><mixed-citation xml:lang="en">Klein M. L. et al. The Epidemiology of Age-Related Macular Degeneration // Am J Ophthalmol. — 2004. — Vol. 137. — P. 486-495.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Thakkinstian A. K. et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration // Hum Mol Genet. — 2006. — Vol. 15. — P. 2784-2790.</mixed-citation><mixed-citation xml:lang="en">Thakkinstian A. K. et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration // Hum Mol Genet. — 2006. — Vol. 15. — P. 2784-2790.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y. J. et al. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors // Arch Ophthalmol. — 2011. — Vol. 129. — P. 344-351.</mixed-citation><mixed-citation xml:lang="en">Chen Y. J. et al. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors // Arch Ophthalmol. — 2011. — Vol. 129. — P. 344-351.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Orlin A. M. et al. Association between high-risk disease loci and response to antivascular endothelial growth factor treatment for wet age-related macular degeneration // Retina. — 2012. — Vol. 32. — P. 4-9.</mixed-citation><mixed-citation xml:lang="en">Orlin A. M. et al. Association between high-risk disease loci and response to antivascular endothelial growth factor treatment for wet age-related macular degeneration // Retina. — 2012. — Vol. 32. — P. 4-9.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kibbin M. S. et al. VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration // Br J Ophthalmol.— 2012.— Vol. 96.— P. 208-212.</mixed-citation><mixed-citation xml:lang="en">Kibbin M. S. et al. VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration // Br J Ophthalmol.— 2012.— Vol. 96.— P. 208-212.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tsuchihashi T. D. et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration // Ophthalmology. — 2011. — Vol. 118. — P. 93-100.</mixed-citation><mixed-citation xml:lang="en">Tsuchihashi T. D. et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration // Ophthalmology. — 2011. — Vol. 118. — P. 93-100.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zarbin M. A., Rosenfeld P. J. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives // Retina. — 2010. — Vol. 30. — P. 1350-1367.</mixed-citation><mixed-citation xml:lang="en">Zarbin M. A., Rosenfeld P. J. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives // Retina. — 2010. — Vol. 30. — P. 1350-1367.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
